Author, as appears in the article.: Hidalgo-Tenorio, Carmen; Vinuesa, David; Plata, Antonio; Davila, Pilar Martin; Iftimie, Simona; Sequera, Sergio; Loeches, Belen; Eduardo Lopez-Cortes, Luis; Carmen Farinas, Mari; Fernandez-Roldan, Concepcion; Javier-Martinez, Rosario; Munoz, Patricia; del Mar Arenas-Miras, Maria; Javier Martinez-Marcos, Francisco; Maria Miro, Jose; Herrero, Carmen; Bereciartua, Elena; De Jesus, Samantha E.; Pasquau, Juan;
Department: Medicina i Cirurgia
URV's Author/s: Iftimie Iftimie, Simona Mihaela
Keywords: Biofilms Bloodstream infection Complicated skin Dalbavancin Endocarditis In-vitro Once-weekly dalbavancin
Abstract: Objectives To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Results Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20euro) and 557 days for IE (283,187.45euro). Conclusions DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
Thematic Areas: Biodiversidade Biotecnología Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Engenharias iii Farmacia Infectious diseases Interdisciplinar Medicina i Medicina ii Medicine (miscellaneous) Microbiology Microbiology (medical) Química Saúde coletiva
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: simonamihaela.iftime@urv.cat simonamihaela.iftime@urv.cat
Author identifier: 0000-0003-0714-8414 0000-0003-0714-8414
Record's date: 2022-07-16
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-019-0329-6
Papper original source: Annals Of Clinical Microbiology And Antimicrobials. 18 (1): 30-
APA: Hidalgo-Tenorio, Carmen; Vinuesa, David; Plata, Antonio; Davila, Pilar Martin; Iftimie, Simona; Sequera, Sergio; Loeches, Belen; Eduardo Lopez-Cortes, (2019). DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Annals Of Clinical Microbiology And Antimicrobials, 18(1), 30-. DOI: 10.1186/s12941-019-0329-6
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Article's DOI: 10.1186/s12941-019-0329-6
Entity: Universitat Rovira i Virgili
Journal publication year: 2019
Publication Type: Journal Publications
Repositori URV